Precipio's Q3 revenue rises 8%
Overview
US cancer diagnostics firm's Q3 revenue rose 8% yr/yr to $7.3 mln
Product revenue grew 40% yr/yr; pathology revenue up 5% yr/yr
Adjusted EBITDA was $0.4 mln, down from $0.5 mln a year earlier
Outlook
Company expects pathology business to support future growth and product development
Result Drivers
PATHOLOGY BUSINESS - Pathology business provided operational and financial foundation for growth
PRODUCT REVENUE GROWTH - Co reported 40% yr/yr increase in product revenue
CASH FLOW - End-of-quarter cash balance exceeded $3.5 mln, vs $2.3 mln in Q3-2025
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $7.3 mln |
Reuters Recommended Reads
Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves
Nov 10 - Co-Diagnostics Q3 revenue rises, operating expenses fall 12%
Nov 9 - Medical tech firm NeurAxis' Q3 revenue jumps on broader insurance coverage
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)